Besides programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), tumor mutation burden (TMB) is a promising biomarker in predicting the outcomes of NSCLC patients with immunotherapy (24–27). Here, PDCD1 is linked to neoplasm.